This analysis demonstrates Cardioform's cost-effectiveness in preventing secondary strokes, implying its potential integration into practice.
Cardioform appears more cost-effective in the prevention of secondary PFO-associated strokes, supporting its adoption in clinical practice.
No takes yet. Share an insight, caveat, or question.
Starmer et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: